Park, Ryan J
Wang, Tim
Koundakjian, Dylan
Hultquist, Judd F
Lamothe-Molina, Pedro
Monel, Blandine
Schumann, Kathrin
Yu, Haiyan
Krupzcak, Kevin M
Garcia-Beltran, Wilfredo
Piechocka-Trocha, Alicja
Krogan, Nevan J
Marson, Alexander
Sabatini, David M
Lander, Eric S
Hacohen, Nir
Walker, Bruce D
Article History
Received: 30 June 2016
Accepted: 15 November 2016
First Online: 19 December 2016
Competing interests
: T.W., D.M.S., and E.S.L. are inventors on a patent application for functional genomics using the CRISPR–Cas system (US 15/141,348), T.W. and D.M.S. are founders of KSQ Therapeutics, a CRISPR functional genomics company, and D.M.S. is a scientific advisor for KSQ Therapeutics. A patent has been filed on the use of Cas9–RNPs to edit the genome of human primary T cells (A.M. and K.S.). A.M. serves as an advisor to Juno Therapeutics, and the laboratory of A.M. has had sponsored research agreements with Juno Therapeutics and Epinomics.